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OBJECTIVES: Diagnosing Appendicitis is a difficult challenge for emergency de-
partments. Appendicitis has been the subject of numerous investigations, but a
diagnostic tool of quality and applicability in the clinical routine has not yet been
identified. We constructed a clinical predictive model for Appendicitis using a
Bayesian network, using a decision analysis approach. METHODS:We designed a
methodology for the construction of decision models to support the process of
clinical diagnosis, which was applied specifically to the diagnosis of Appendicitis.
The methodology starts with a multiple correspondence analysis (MCA) for the
selected variables with the highest power of discrimination, based on which an
initial Bayesian network is proposed. This network was refined with the support of
a group of medical experts in the diagnosis, to define the final structure of the
Bayesian network. Finally, the model is validated through cross-validation
method. For validation we used Sanabria, Bermudez, Dominguez and Serna’s
(2007) database, which consists of 349 patients with suspected Appendicitis.
RESULTS: The implementation of the methodology produced results in a Bayesian
network that included eleven variables associated to signs, symptoms and labora-
tory results. The results of the proposedmodel, with respect tomedical assessment
without specialized tools for diagnosis, showed significant improvements in accu-
racy, from 81% to 94%; in sensitivity, from 85% to 98%; and in specificity, from 76%
to 90%. CONCLUSIONS: The Bayesian network constructed based on the MCA im-
proved the accuracy of Appendicitis diagnosis in comparison to othermodels avail-
able in the literature, among which are the Alvarado score and the Fenÿo score.
Additionally, the constructed Bayesian network has characteristics that facilitate
its applicability in the clinical routine.
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OBJECTIVES: To evaluate the usability of an electronic patient-reported outcome
(ePRO) diary in accordancewith recommendations for usability testing in the ISPOR
ePROTask Force Report.METHODS: TheNighttime Symptoms of COPD Instrument
(NiSCI) and Early Morning Symptoms of COPD Instrument (EMSCI) were pro-
grammed into a handheld device (HTC HD2®). The device and instructions [Quick
Reference Guide (QRG)] were evaluated in two rounds of testing. Each round con-
sisted of user acceptance testing (UAT) by researchers, followed by usability assess-
ment by COPD patients. Patients were trained to use the device and completed the
diary five to seven days at home, followed by a qualitative interview in the clinic
about the device’s usability. Time and duration of diary completion were recorded
on the device each day. At the interview, participants also completed a Device
Usability Questionnaire and answered questions regarding their background and
technology proficiency. RESULTS: Mean age of the sample (N15) was 60 years,
(range 40–87); 60% were male. All participants were diagnosed with COPD and
experienced symptoms at night or earlymorning, per inclusion criteria. Nine (60%)
reported being “moderately technically proficient”. Feedback from the first round
(n5) informed the refinement of screen layout, skip patterns, and QRG, before a
second round of interviews. Results from the second round (n10) confirmed ‘pop-
up’ message wording, readability, screen clarity, and comprehension. Of 15 partic-
ipants, 66.7% found the device “very easy” to learn and 73.3% rated overall use “very
easy.” Participants averaged 3.5 minutes for diary completion; completion time
decreased over time. CONCLUSIONS: This usability study confirmed that COPD
patients found the electronic, HTC HD2®-based NiSCI and EMSCI patient-friendly,
easy to use, and suitable for daily assessment of COPD symptoms.
PMD62
A SIMULATED CONTROL GROUP COMPARATIVE APPROACH TO USING PHASE I
TRIAL DATA TO ASSESS THE OUTCOMES OF A NOVEL TREATMENT FOR ACUTE
KIDNEY FAILURE
Hughes KE1, Giannola L2, Li B1, Hammelman E1, Kelly P1
1Avalere Health LLC, Washington, DC, USA, 2CytoPherx, Ann Arbor, MI, USA
OBJECTIVES: To develop a simulated “control” group to compare Phase 1 trial data
from acute kidney failure (AKF) patients receiving novel renal-replacement ther-
apy (RRT) with a Selective Cytopheretic Device (SCD), and to compare clinical out-
comes and economic impact of SCD treatment to hemodialysis.METHODS: Clini-
cians collected data on the first 35 patients treated with the SCD. To add a second
interventional trial arm, the developer needed a simulated control group (control)
for comparative purposes. Data from the literature and 2009 MEDPAR files were
utilized to develop a control with clinical characteristicsmatching those of the trial
population but undergoing hemodialysis. Critically, cohorts were matched on di-
agnosis, SOFA score,mechanical ventilation, sepsis, and RRT treatment. Secondary
sources contained mortality data, survivor RRT dependency, and resource con-
sumption units for the control – variables captured for trial patients. Unit resource
costs for trial patients were based on MedPAR data and the literature. SCD costs
were manufacturer-supplied. We computed relative resource cost impact for both
cohorts from imputed units and unit costs. RESULTS: Our methods yielded suffi-
cient information to compare clinical outcomes and budget impact of SCD treat-
ment relative to hemodialysis. SCD-treated patients showed 60-daymortality rates
of 31% versus control rates 50%. Savings from reduced ALOS in trial patients
exceeded incremental costs of SCD treatment. We estimated future payer budget
impact using USRDS (2010) treatment costs for survivors in both groups with con-
tinuing RRT needs progressing to ESRD care. Results showed cost avoidance of
$2.0M for 100 AKF patients. Confidence in the model was supported by sensitiv-
ities to ICU ALOS and survival rates, non-estimated variables for both cohorts. The
model withstood key variable manipulation of 20% before conclusions changed
directionally. CONCLUSIONS: A simulated control approach is a cost-effective
means for small manufacturers to conduct early hypothesis testing and build a
foundation for later-stage development.
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OBJECTIVES: The objective of this study was to determine the impact of adverse
events common to opiate use upon post-operative length of stay. METHODS: The
study was based in Cardiff and the Vale of Glamorgan in 2004. All admissions
involving a surgical procedure, other than those specifically relating to the gastro-
intestinal system, were extracted and those for patients with a secondary diagno-
sis of either constipation (ICD-10 K59), nausea and vomiting (R11), pruritus (L29),
headache (R51), dizziness (R42) or fever of unknown origin (R50) were flagged.
These cases werematched by age (5 year age banded) and sex to controls admitted
with the same procedure (defined by three character OPCS-4 code). Length of stay
for cases versus controls was compared using the Wilcoxon rank signed test.
RESULTS: Of 116,309 hospital episodes, 58,025 included a surgical procedure. Of
these 285 included one of the diagnoses listed above of which 234 (82.1%) could be
matchedwith an age and sex control. Mean age of subjects was 53.7 (sd 23.5) and 96
(41.%) were male. Overall length of stay was greater for cases (median  11.0 days
[IQR 6.0-20.25] versus controls (5.0 days [1.0-14.0] p0.001. This was true for most
subgroups: constipation 14.5 days [7-23.25] versus 6 days [2-19] p 0.001; nausea
and vomiting 14 days [6-22.25] versus 7 days [1-19.25] p0.001; pruritus 5 days
[3-12] versus 1 days [1-3] p0.027; headache 13 days [6-39.5] versus 1.5 days [0-6.25]
p0.011 and fever 8 days [4.5-12.5] versus 1 days [0-8] p0.011. There was no
significant difference for dizziness 8 days [1.75-13.5] versus 2 days [0-10.5] p0.229.
CONCLUSIONS: This study demonstrates that adverse events commonly associ-
ated with opioid use have a significant impact on post-operative length of stay.
Reducing these events could have benefits both in terms of the well-being of the
individual patient and overall healthcare costs.
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OBJECTIVES: Demand for a primary TKA is increasing and projected to grow expo-
nentially by 2030. Comorbidities have been identified as a contributor to increased
postoperative length of the stay (LOS) of the patient in the hospital, a major con-
tributor to the cost of TKA. The purpose of the study is to assess the effect of
comorbidities [diabetes, hypertension, obesity (bmi 30 kg/m2), chronic back
pain(CBP), insomnia, cancer, osteoporosis], on patient LOS after elective TKA.
METHODS: Patients 40 years old with a primary unilateral TKA, excluding those
with a 2nd TKA surgery within the year, were retrospectively extracted from a
clinical orthopedic database between September 1, 2008 to November 30, 2010. LOS
and comorbidities were obtained by chart abstraction from the electronic medical
record. Unadjusted and adjusted odds ratios (OR) of having a LOS 3 days were
calculated for each comorbidity. Using logistic regression analysis, ORs were ad-
justed for age, gender, pre-operative physical/mental health and preoperative level
of physical activity. RESULTS:A total of 174 patientswith an average age of 63.8 (SD
10.2, 41-85) years were included in the study; 63% (110) were female and 56% (98)
were obese. 75% of the patient population was discharged in 3 days. Unadjusted
analysis identified those with diabetes, hypertension, obesity, CBP, cancer and
osteoporosis as being more likely to have a LOS 3 than those without these co-
morbidities. In adjustedORs, the likelihood of having a LOS3 dayswere 7.88 times
(95% confidence interval[CI]2.28-27.21) among patients with osteoporosis and
1.87 times (95% CI1.20-9.96) among patients with a history of cancer versus those
without these comorbidities. CONCLUSIONS: Few studies have focused on specific
comorbidities that influence LOS. We found that preoperative diagnosis of osteo-
porosis or cancer increased the LOS following elective TKA. Previous determinants,
age, gender, pre-operative level of physical activity, preoperative and physical
health were not influential.
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OBJECTIVES: The objective of this study was to utilize the BOLD database to ana-
lyze percent BMI loss after bariatric surgery. Of particular interest was the deter-
mination of predictors to help explain the large variation in bariatric surgery
success.METHODS: The dataset extracted for analysis consisted of patients age 21
or older having their first bariatric surgery (laparoscopic adjustable gastric band
(LAGB), Roux-en-y gastric bypass (RYGB), or vertical sleeve gastrectomy (VSG)) be-
tween January 1, 2007 and February 26, 2010, with pre-surgery BMI of at least 30, a
baseline visit and at least one postoperative visit. Subpopulations with postopera-
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